文献速递泌尿生殖与妇科肿瘤放疗

癌症干细胞与CD44及局部晚期宫颈癌放化疗后的结局:一项前瞻性研究的结果

Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-09-11

这项前瞻性研究纳入2013年10月至2015年12月的150例IB2-IVA期宫颈鳞癌患者,治疗前和治疗后活检检测SOX-2、OCT-4、Nanog、CD44和Podoplanin表达。中位随访30个月,3年无病生存率为87%。多因素分析显示,中度至高度癌症干细胞表达且CD44低状态独立预测无局部区域复发生存率下降(HR=8.8)。

要点

  • 150例局部晚期宫颈鳞癌患者接受同步放化疗,中位A点剂量83 Gy,中位化疗4周期。
  • 中度至高度癌症干细胞表达且CD44低状态独立预测无局部区域复发生存率下降,HR=8.8。
  • FIGO分期和体外照射后残留肿瘤预测无病生存率下降。

核心结论

  • 癌症干细胞蛋白的存在和CD44缺失独立预测局部晚期宫颈癌局部区域控制下降。
  • 作者认为需要进一步研究干细胞与CD44生物学的相互作用。

研究设计与样本

  • 前瞻性研究,纳入2013年10月至2015年12月的150例IB2-IVA期宫颈鳞癌患者。
  • 治疗前和治疗后活检,采用免疫组化检测SOX-2、OCT-4、Nanog、CD44和Podoplanin。
  • 所有患者接受同步放疗和近距离放疗至A点等效剂量80至84 Gy,同步每周顺铂化疗。

主要发现

  • 基线时SOX-2、OCT-4、Nanog、CD44和Podoplanin中度至强免疫组化表达分别见于12.8%、4.8%、24.4%、15.5%和1.3%的患者。
  • 中位随访30个月(范围3-51个月),局部区域复发和远处复发分别见于12.2%和23.1%的患者,其中4.7%同时有局部和远处复发。
  • 3年无病生存率为87%。
  • 多因素分析中,中度至高度癌症干细胞表达且CD44低状态独立预测无局部区域复发生存率下降(HR=8.8;95%CI 1.0-77.2;P<.04)。
  • FIGO分期(HR=2.6;95%CI 1.3-5.4;P=.004)和体外照射后残留肿瘤(HR=3.5;95%CI 1.8-6.5;P=.0001)预测无病生存率下降。

关键数值与推荐

  • 中位A点剂量为83 Gy(范围46-89 Gy),中位化疗4周期(范围0-6周期)。
  • 多因素分析中,中度至高度癌症干细胞表达且CD44低状态预测无局部区域复发生存率下降的HR=8.8(95%CI 1.0-77.2;P<.04)。
  • FIGO分期预测无病生存率下降的HR=2.6(95%CI 1.3-5.4;P=.004)。
  • 体外照射后残留肿瘤预测无病生存率下降的HR=3.5(95%CI 1.8-6.5;P=.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要进一步研究干细胞与CD44生物学的相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although cancer stem cells (CSCs) have been reported across solid tumors, there is a dearth of data regarding CSC and its impact on outcomes of cervical cancer. METHODS AND MATERIALS: From October 2013 to December 2015, patients with squamous cancer of the cervix (stage IB2-IVA) were included. Pretreatment and posttreatment biopsy was obtained and immunohistochemistry was performed for SOX-2, OCT-4, Nanog, CD44, and Podoplanin. All patients received concurrent radiation and brachytherapy to an equivalent dose of 80 to 84 Gy to point A with concurrent weekly cisplatin. Correlation of CSC expression was performed with known prognostic factors. The effect of stem cell expression on disease outcomes was tested within multivariate analysis. RESULTS: One hundred fifty patients were included. The median dose to point A was 83 Gy (46-89 Gy) and a median of 4 cycles (range, 0-6 cycles) of chemotherapy was administered. At baseline, moderate to strong immunohistochemical expression of SOX-2, OCT-4, Nanog, CD44, and Podoplanin was observed in 12.8%, 4.8%, 24.4%, 15.5%, and 1.3% of patients, respectively. At median follow-up of 30 months (range, 3-51 months), locoregional and distant relapse was observed in 12.2% and 23.1% of patients, of whom 4.7% had both local and distant relapse. The 3-year disease-free survival rate was 87%. On multivariate analysis, moderate to high CSC expression and CD44 low status (hazard ratio [HR] = 8.8; 95% confidence interval [CI], 1.0-77.2; P < .04) independently predicted for locoregional relapse-free survival. International Federation of Gynecology and Obstetrics stage (HR = 2.6; 95% CI, 1.3-5.4; P = .004) and presence of residual tumor after external radiation (HR = 3.5; 95% CI, 1.8-6.5; P = .0001) predicted for a detriment in disease-free survival. CONCLUSIONS: The presence of stem cell proteins and loss of CD44 independently predicts for reduced locoregional control in locally advanced cervical cancer. Further investigation into the interaction of stem cell and CD44 biology is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chopra S, Deodhar K, Pai V, et al. Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study. Int J Radiat Oncol Biol Phys. 2018. PMID: 30213750. doi:10.1016/j.ijrobp.2018.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。